Please check your internet connection and try again.
# Isoxsuprine Hydrochloride
## Overview
Isoxsuprine hydrochloride is a peripheral vasodilator. Its exact mechanism of action is not fully understood but is thought to involve direct relaxation of vascular smooth muscle.
## Primary Indications
* Treatment of peripheral vascular diseases such as intermittent claudication and Raynaud's disease.
* Historically used for premature labor, but this indication is no longer recommended due to safety concerns.
## Adult Dosing
* **Intermittent Claudication/Peripheral Vascular Disease:** 10 mg to 20 mg orally every 3 to 4 times daily. Doses may be increased to 40 mg four times daily.
## Pediatric Dosing
There is no established pediatric dosing for isoxsuprine hydrochloride. Its use in children is generally not recommended.
## Dose Adjustments
No specific dose adjustments are routinely recommended for renal or hepatic impairment. However, caution should be exercised in patients with severe disease due to potential accumulation.
## Contraindications
* Hypersensitivity to isoxsuprine hydrochloride.
* Do not use in patients where peripheral vasodilation is inadvisable (e.g., in the presence of hypotension or tachycardia).
* Avoid use in pregnancy for tocolysis due to potential adverse effects.
## Adverse Effects
* **Common:** Flushing, hypotension, dizziness, nausea, vomiting, rash, weakness, abdominal distress.
* **Less Common:** Tachycardia, palpitations, drowsiness, epigastric distress.
## Key Drug Interactions
* **Antihypertensives:** Isoxsuprine may potentiate the effects of antihypertensive medications, leading to excessive hypotension.
* **Vasodilators:** Additive hypotensive effects may occur when used concurrently with other vasodilators.
## Monitoring
* Blood pressure and heart rate.
* Symptoms of peripheral vascular disease.
* Signs of adverse effects.
## Clinical Pearls
* Effectiveness in peripheral vascular disease is controversial, and clinical benefit may be marginal.
* Patient education regarding potential dizziness and postural hypotension is important.
* Discontinue therapy if no clinical improvement is observed after a reasonable trial period.
***
*Disclaimer: This information is intended for clinical use and does not substitute for professional medical judgment. Always verify current prescribing information with the official product labeling or a reliable drug information resource before making clinical decisions.*
